

FIG. 1




FIG. 2




FIG. 2 continued




FIG. 3




FIG.3 continued





FIG.3 continued



7/47

FIG. 4




FIG. 4 continued




FIG. 4 continued




FIG. 5




FIG. 5 continued




FIG. 5 continued





FIG. 5 continued




FIG. 6





FIG. 6 continued



17/47

FIG. 7




FIG. 7 continued







FIG. 7 continued



F



20/47

FIG. 8





FIG. 8 continued



22/47

FIG. 8 continued






FIG. 9



24/47

FIG. 9 continued




FIG. 10





FIG. 10 continued



27/47

FIG. 10 continued




FIG. 11




FIG. 11 continued




FIG. 12




FIG. 12 continued






FIG. 12 continued




G



31/47

FIG. 12 continued



H




FIG. 12 continued




FIG. 13

A






FIG. 13 continued



34/47

FIG. 13 continued




FIG. 14







FIG. 14 continued


C



D



E



F




FIG. 14 continued




FIG. 14 continued





FIG. 15



40/47

FIG. 15 continued





FIG. 16



41/47

FIG. 16 continued




FIG. 17

A***Sitagliptin:**

- Specific DPP4 inhibitor
- Not DPP8 or 9

	IC50/μM	
	Talabostat	Sitagliptin
DPP4	0.002	0.018
DPP8	0.0015	48
DPP9	0.00076	100

FIG. 17 continued
293T-ASC-GFP




FIG. 18




FIG. 18 continued






FIG. 19




44/47

FIG. 19 continued



45/47

FIG. 20



“Ballooning” is characteristic of pyroptosis

46/47

FIG. 21




FIG. 22




FIG. 23




FIG. 24

